Publications Repository

Publications Repository

View Item 
  •   Home
  • ICR Divisions
  • Cancer Therapeutics
  • View Item
  • Home
  • ICR Divisions
  • Cancer Therapeutics
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Mechanism and non-mechanism based imaging biomarkers for assessing biological response to treatment in non-small cell lung cancer.

Thumbnail
View/Open
Published version (272.5Kb)
Publication Date
2016-05
ICR Author
deSouza, Nandita
O'Brien, Mary
Ahmed, Merina
Yap, Timothy
Popat, Sanjay
Weller, Alexander
Author
Weller, A
O'Brien, MER
Ahmed, M
Popat, S
Bhosle, J
McDonald, F
Yap, TA
Du, Y
Vlahos, I
deSouza, NM
Type
Journal Article
Metadata
Show full item record
Abstract
Therapeutic options in locally advanced non-small cell lung cancer (NSCLC) have expanded in the past decade to include a palate of targeted interventions such as high dose targeted thermal ablations, radiotherapy and growing platform of antibody and small molecule therapies and immunotherapies. Although these therapies have varied mechanisms of action, they often induce changes in tumour architecture and microenvironment such that response is not always accompanied by early reduction in tumour mass, and evaluation by criteria other than size is needed to report more effectively on response. Functional imaging techniques, which probe the tumour and its microenvironment through novel positron emission tomography and magnetic resonance imaging techniques, offer more detailed insights into and quantitation of tumour response than is available on anatomical imaging alone. Use of these biomarkers, or other rational combinations as readouts of pathological response in NSCLC have potential to provide more accurate predictors of treatment outcomes. In this article, the robustness of the more commonly available positron emission tomography and magnetic resonance imaging biomarker indices is examined and the evidence for their application in NSCLC is reviewed.
URL
https://repository.icr.ac.uk/handle/internal/693
Collections
  • Cancer Therapeutics
  • Clinical Studies
  • Radiotherapy and Imaging
Version of record
10.1016/j.ejca.2016.02.017
Subject
Humans
Carcinoma, Non-Small-Cell Lung
Lung Neoplasms
Antineoplastic Agents
Radiopharmaceuticals
Observer Variation
Positron-Emission Tomography
Magnetic Resonance Imaging
Catheter Ablation
Treatment Outcome
Immunotherapy
Cell Proliferation
Cell Hypoxia
Forecasting
Molecular Targeted Therapy
Tumor Microenvironment
Multimodal Imaging
Biomarkers, Tumor
Positron Emission Tomography Computed Tomography
Research team
Medicine Drug Development Unit (de Bono)
Thoracic Oncology
Treatment of thoracic tumours
Lung Radiotherapy
Magnetic Resonance
Language
eng
Date accepted
2016-02-18
License start date
2016-05
Citation
European journal of cancer (Oxford, England : 1990), 2016, 59 pp. 65 - 78

Browse

All of ICR repositoryICR DivisionsIssue dateAuthorsTitlesSubjectsThis collectionIssue dateAuthorsTitlesSubjects

Statistics

Most popular itemsStatistics by countryMost popular authors
  • Login
  • Registered office: The Institute of Cancer Research, 123 Old Brompton Road, London, SW7 3RP
    A Charity, Not for Profit. Company Limited by Guarantee.
    Registered in England No. 534147. VAT Registration No. GB 849 0581 02.